default author photo

Joseph S. Spina

AbbVie Inc.

SCHOLARLY PAPERS

2

DOWNLOADS

211

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

­Navitoclax Reduces Biomarkers of Senescence, SASP, and Neurodegeneration in Aged Nonhuman Primates

Number of pages: 26 Posted: 14 Mar 2024
Edward Greenberg, Martin J. Voorbach, Alexandra A. Smith, David R. Reuter, Yuchuan Zhuang, Ji-Quan Wang, Dustin W. Wooten, Elizabeth Asque, Min Hu, Carolin Hoft, Ryan C. Duggan, Matthew Townsend, Karin M. Orsi, Karen Dalecki, Willi Amberg, Lori Duggan, Heather Knight, Joseph S. Spina, Yupeng He, Kennan C. Marsh, Vivian Zhao, Suzanne E. Ybarra, Jennifer E. Mollon, Yuni Fang, Aparna Vasanthakumar, Susan V. Westmoreland, Mathias Droescher, Sjoerd J. Finnema and Hana Florian
AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG - Neuroscience Research, AbbVie Inc. and AbbVie Inc.
Downloads 120 (596,393)

Abstract:

Loading...

Senescence, neuropathology, navitoclax, senolytics, disease-modification, inflammation, SASP, neurodegeneration, monkeys, non-human primates, NHP

2.

Navitoclax Safety, Tolerability, and Effect on Biomarkers of Senescence and Neurodegeneration in Aged Nonhuman Primates

Number of pages: 25 Posted: 17 Jul 2024
Edward Greenberg, Martin J. Voorbach, Alexandra A. Smith, David R. Reuter, Yuchuan Zhuang, Ji-Quan Wang, Dustin W. Wooten, Elizabeth Asque, Min Hu, Carolin Hoft, Ryan C. Duggan, Matthew Townsend, Karin M. Orsi, Karen Dalecki, Willi Amberg, Lori Duggan, Heather Knight, Joseph S. Spina, Yupeng He, Kennan C. Marsh, Vivian Zhao, Suzanne E. Ybarra, Jennifer E. Mollon, Yuni Fang, Aparna Vasanthakumar, Susan V. Westmoreland, Mathias Droescher, Sjoerd J. Finnema and Hana Florian
AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, AbbVie Inc., AbbVie Inc., AbbVie Inc., AbbVie Deutschland GmbH & Co. KG - Neuroscience Research, AbbVie Inc. and AbbVie Inc.
Downloads 91 (736,406)

Abstract:

Loading...

Senescence, Neuropathology, navitoclax, senolytics, disease-modification, Inflammation, sasp, neurodegeneration, monkeys, non-human primates